Survival analysis further revealed that higher RASON expression was linked to shorter survival in KRAS-mutant patients (Fig. 1K), In contrast, RASON expression was not associated with tumor stage, macrophage infiltration, or survival in KRAS wild-type patients (Fig. S2J-N). This evidence concerns the gene KRAS and neoplasm.